Home arrow Contact

Cervarix - Glaxo HPV Vaccine Filed With FDA

PDF Print E-mail
Written by Vaccine Rx Staff   
Friday, 30 March 2007
Tag it:
Delicious
Furl it!
Spurl
NewsVine
Reddit
YahooMyWeb
Technorati
Digg
feedmelinks
Stumble
YahooMyWeb

GlaxoSmithKline (NYSE: GSK) announced today that the company has submitted a Biologics License Application (BLA) for CERVARIX® (human papillomavirus vaccine, AS04 adjuvant-adsorbed), its cervical cancer candidate vaccine, to the U.S. Food and Drug Administration (FDA).  For this candidate vaccine, GSK selected a novel proprietary adjuvant system called AS04, intended to enhance immune response and increase duration of protection.

“Today’s filing is an important milestone for GSK and reflects our commitment to help prevent cervical cancer, the second most common cancer among younger women,” said JP Garnier, CEO of GlaxoSmithKline, one of the world’s leading vaccine manufacturers. “We believe that the best possible protection against cervical cancer will include routine screening together with a vaccine designed to provide targeted, durable protection against the most common cancer-causing virus types.”

The BLA for the GSK cervical cancer candidate vaccine includes data from clinical trials in almost 30,000 females 10 to 55 years of age and reflects an ethnically diverse population. The submission also contains data from the largest Phase III cervical cancer vaccine efficacy trial to date, which was conducted around the world in more than 18,000 females 15 to 25 years of age.

“We are pleased to submit this file to the FDA,” said Barbara Howe, MD, Vice President and Director, North American Vaccine Development Organization, at GlaxoSmithKline. “It includes a considerable amount of data for virus types 16 and 18 that cause 70 percent of cervical cancer cases worldwide, as well as data for other virus types that can lead to cervical cancer. We look forward to presenting study results in the coming months.”

The GSK cervical cancer candidate vaccine is formulated with a proprietary adjuvant system called AS04, containing aluminum hydroxide and monophosphoryl lipid A (MPL®). Published data have shown that the GSK cervical cancer candidate vaccine formulated with AS04 provides a stronger and longer lasting immune response compared to the same GSK vaccine composition formulated with a traditional aluminum hydroxide adjuvant.

Tag it:
Delicious
Furl it!
Spurl
NewsVine
Reddit
YahooMyWeb
Technorati
Digg
feedmelinks
Stumble
YahooMyWeb
Tags:
Click to add your tags...,
Comments (0) >> feed
Write comment

You must be logged in to a comment. Please register if you do not have an account yet.


busy
 
< Prev   Next >

Login Form






Lost Password?
No account yet? Register

Syndicate